Milestone Scientific Appoints Senior Industry & Sales Executive Arjan Haverhals as President & CEO of Wand Dental Inc. Subsidiary
News & Press
June 2, 2020 8:30 am
Mr. Haverhals to also help drive sales and marketing initiatives for CompuFlo® Epidural Instrument
ROSELAND, NJ / June 2, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has appointed Jan Adriaan (Arjan) Haverhals as Chief Executive Officer of Wand Dental, Inc., a wholly-owned subsidiary of Milestone Scientific, Inc. Mr. Haverhals replaces Gian Domenico Trombetta who will remain a member of Milestone Scientific’s Board of Directors. In addition to his responsibilities with Wand Dental, Mr. Haverhals will also be involved in helping drive new sales and marketing initiatives for the CompuFlo® Epidural Instrument.
Mr. Haverhals brings more than 30 years of sales, marketing, product development, and international expansion experience within the medical device, pharmaceutical, and other industries. Mr. Haverhals has been responsible for the growth and profitability of both startups and global industry leaders, organically and through strategic acquisitions. Prior to joining Wand Dental and Milestone Scientific, Mr. Haverhals was senior vice president of sales at Xcentric Mold & Engineering, where he was instrumental in increasing sales productivity and efficiency for the company’s prototype injection molding services, which included leading healthcare company clients. Previously, at Straumann, LLC, a global leader in manufacturing medical and dental devices with over $1 billion in sales, he held a series of senior sales and marketing roles including vice president of customer marketing & education, where he oversaw all product franchises and led the launch of more than 30 products in the North American market, resulting in double-digit growth. He also served as senior vice president for the Nordic Region at Straumann AB, senior vice president of global sales digital solutions, which included oversight of the strategic acquisition of Etkon; and served as vice president of the Prosthetics Business Unit, where he introduced a new implant and prosthetics product line within a new market segment. He also served as vice president of global marketing & sales at Elkem AS, one of Norway’s largest industrial companies. Previously, Mr. Haverhals served as executive vice president of marketing & sales at Cresco Ti Systems Sàrl, a global dental implant company, where he was responsible for turning around and managing global sales, marketing, international business, where he achieved over 100% return on investment for shareholders. Mr. Haverhals holds an MS in Pharmacy from the University of Leyden in the Netherlands.
Leonard Osser, CEO of Milestone Scientific, stated, “I am very pleased to announce the appointment of Arjan as President and CEO of our dental subsidiary. We thank Gian Domenico for his commitment as CEO of Wand Dental and look forward to his ongoing support of Arjan in his new leadership role. Arjan brings more than 30 years of senior management experience and an impressive track record leading rapid growth companies and initiatives across a broad range of industries, including dental products. We believe having such a strategic global growth leader will support our initiative to more aggressively market our dental instruments and handpieces on a global basis over the coming years as we evaluate new collaboration and distribution opportunities. Additionally, we look forward to Arjan’s contributions as we commercialize our CompuFlo® Epidural Instrument in the U.S. and abroad.”
Arjan Haverhals commented, “I am thrilled to accept this position and look forward to helping grow Wand Dental, as well as accelerate the launch of the CompuFlo® Epidural Instrument and other medical products based on the proprietary Dynamic Pressure Sensing Technology™ (DPS) technology. I’m impressed with The Wand’s existing foothold within the market, and opportunities for growth. With the right focus, I believe we can help bring this business to the next level. At the same time, I look forward to supporting the growth of the CompuFlo® Epidural Instrument in both the domestic and international markets.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
SOURCE: Milestone Scientific, Inc.